Edgar Tracker

ENGN enGene Therapeutics Inc.

Nasdaq, Nasdaq · CIK 1980845 · Biological Products, (No Diagnostic Substances)

SEC company page

Public articles

No public articles yet. Follow ENGN to track filings and write notes.

Recent filings

–

Form Filed Title Accession
10-Q2026-09-0810-Q0001193125-26-384383
8-K2026-09-082.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits0001193125-26-384380
SCHEDULE 13G/A2026-08-14—0001193125-26-352637
SCHEDULE 13G/A2026-08-14—0001231919-26-000931
SCHEDULE 13G/A2026-08-14—0001172661-26-003477
SCHEDULE 13G/A2026-08-13—0002005369-26-000051
SCHEDULE 13G/A2026-08-12—0001140361-26-032512
8-K2026-08-118.01 Other Events · 9.01 Financial Statements and Exhibits0001193125-26-344559
32026-07-22—0000929638-26-002667
32026-07-22—0000929638-26-002666
SCHEDULE 13G2026-07-22—0001636587-26-000058
8-K2026-07-177.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits0001193125-26-307795
8-K2026-07-165.02 Departure/Election of Directors or Principal Officers · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits0001193125-26-305418
8-K/A2026-06-182.05 Costs Associated with Exit or Disposal Activities · 5.02 Departure/Election of Directors or Principal Officers0001193125-26-275815
10-Q2026-06-1510-Q0001193125-26-270386
8-K2026-06-152.02 Results of Operations and Financial Condition · 2.05 Costs Associated with Exit or Disposal Activities · 5.02 Departure/Election of Directors or Principal Officers · 7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits0001193125-26-270384
8-K2026-06-105.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits0001193125-26-265830
SCHEDULE 13G/A2026-05-15—0001172661-26-002215
SCHEDULE 13G/A2026-05-14—0001373604-26-000042
SCHEDULE 13G2026-05-13—0001373604-26-000041